Leukotriene B4 mediates vascular smooth muscle cell migration through αvβ3 integrin transactivation

Atherosclerosis

Volumn 212, Issue 2, 2010, Pages 406-413

  Moraes, João ^a   Assreuy, Jamil ^b   Canetti, Cláudio ^c   Barja Fidalgo, Christina ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

v 3 integrin; FAK; LTB4; PI3K; SMC

Indexed keywords

1 [3 (4 BIPHENYLYLMETHYL) 4 HYDROXYCHROMAN 7 YL]CYCLOPENTANECARBOXYLIC ACID; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ACTIN; ANGIOTENSIN II; FOCAL ADHESION KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; KISTRIN; LEUKOTRIENE B4; PERTUSSIS TOXIN; ENZYME INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; VITRONECTIN RECEPTOR;

ANIMAL CELL; ARTICLE; CARDIOVASCULAR DISEASE; CELL MIGRATION; CHEMOTAXIS; CYTOSKELETON; MOLECULAR DYNAMICS; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; ANIMAL; BLOOD VESSEL INJURY; CELL MOTION; CELL NUCLEUS; CYTOLOGY; METABOLISM; PHYSIOLOGY; THORACIC AORTA; TRANSCRIPTION INITIATION;

ANIMALS; AORTA, THORACIC; CELL MOVEMENT; CELL NUCLEUS; CHEMOTAXIS; ENZYME INHIBITORS; INTEGRIN ALPHAVBETA3; LEUKOTRIENE B4; MUSCLE, SMOOTH, VASCULAR; NADPH OXIDASE; PHOSPHORYLATION; RATS; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; VASCULAR SYSTEM INJURIES;

EID: 77957721478     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.06.009     Document Type: Article

References (33)

1. Libby P. Inflammation in atherosclerosis. Nature 2002, 420(6917):868-874. 19-6.
2. Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006, 6:508-519.
3. De Caterina R., Mazzone A., Giannessi D., et al. Leukotriene B4 production in human atherosclerotic plaques. Biomed Biochim Acta 1988, 47:S182-S185.
4. Spanbroek R., Grabner R., Lotzer K., et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 2003, 100:1238-1243.
5. Back M. Leukotriene receptors: crucial components in vascular inflammation. ScientificWorldJournal 2007, 7:1422-1439.
6. 4 and BLT1 in smooth muscle cell recruitment. Circulation 2005, 112(4):578-586. 26.
7. Luchtefeld M., Drexler H., Schieffer B. 5-Lipoxygenase is involved in the angiotensin II-induced NAD (P)H-oxidase activation. Biochem Biophys Res Commun 2003, 308:668-672.
8. Back M., Bu D.X., Branstrom R., Sheikine Y., Yan Z.Q., Hansson G.K. Leukotriene B4 signaling through NF-kB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci USA 2005, 102(48):17501-17506. 29.
9. Lu X., Lu D., Scully M.F., Kakkar V.V. The role of integrin-mediated cell adhesion in atherosclerosis: pathophysiology and clinical opportunities. Curr Pharm Des 2008, 14(22):2140-2158.
10. Davenpeck K.L., Marcinkiewicz C., Niculescu D.W.R., Shi Y., Martin J.L., Zalewski A. Regional differences in integrin expression role of α5β1 in regulating smooth muscle cell functions. Circ Res 2001, 88:352-358.
11. Egidius H.J., Heerkens, Ashley S., Izzard, Anthony M. Heagerty integrins, vascular remodeling, and hypertension. Hypertension 2007, 49:1-4.
12. Burtea C., Laurent S., Murariu O., et al. Molecular imaging of alpha v beta3 integrin expression in atherosclerotic plaques with a mimetic of RGD peptide grafted to Gd-DTPA. Cardiovasc Res 2008, 78(1):148-157. 1.
13. Jones J.I., Prevette T., Gockerman A., Clemmons D.R. Ligand occupancy of the alpha-V-beta3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor. Proc Natl Acad Sci USA 1996, 93(6):2482-2487. 19.
14. Varadarajulu J., Laser M., Hupp M., Wu R., Hauck C.R. Targeting of alpha (v) integrins interferes with FAK activation and smooth muscle cell migration and invasion. Biochem Biophys Res Commun 2005, 331(2):404-412. 3.
15. Ringleb P.A. Thrombolytics, anticoagulants, and antiplatelet agents. Stroke 2006, 37(2):312-313.
16. Juliano D., Wang Y., Marcinkiewicz C., Rosenthal L.A., Stewart G.J., Niewiarowski S. Disintegrin interaction with alpha V beta 3 integrin on human umbilical vein endothelial cells: expression of ligand-induced binding site on beta 3 subunit. Exp Cell Res 1996, 225:132-142.
17. Coelho A.L., De Freitas M.S., Mariano-Oliveira A., et al. RGD- and MLD-disintegrins, jarastatin and EC3, activate integrin-mediated signaling modulating the human neutrophils chemotaxis, apoptosis and IL-8 gene expression. Exp Cell Res 2004, 292(2):371-384. 15.
18. Lo I.C., Shih J.M., Jiang M.J. Reactive oxygen species and ERK 1/2 mediate monocyte chemotactic protein-1-stimulated smooth muscle cell migration. J Biomed Sci 2005, 12(2):377-388.
19. Giancotti F.G., Ruoslahti E. Integrin signaling. Science 1999, 285(5430):1028-1032. 13.
20. Chen H.C., Guan J.L. Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase. Proc Natl Acad Sci USA 1994, 91:10148-10152.
21. Cary L.A., Guan J.L. Focal adhesion kinase in integrin-mediated signaling. Front Biosci 1999, 15(4):D102-D113.
22. Schlapfer D.D., Hauck C.R., Sieg D.J. Signaling through focal adhesion kinase. Prog Biophys Mol Biol 1999, 14:1680-1688.
23. Morello F., Perino A., Hirsch E. Phosphoinositide 3-kinase signalling in the vascular system. Cardiovasc Res 2009, 82(2):261-271. 1.
24. Sundaram M.V. RTK/Ras/MAPK signaling. WormBook 2006, 11:1-19.
25. Walsh C.T., Stupack D., Brown J.H. G protein-coupled receptors go extracellular: RhoA integrates the integrins. Mol Interv 2008, 8(4):165-173.
26. Choi E.T., Khan M.F., Leidenfrost J.E., et al. Beta3-integrin mediates smooth muscle cell accumulation in neointima after carotid ligation in mice. Circulation 2004, 109(12):1564-1569. 30.
27. de Winther M.P., Kanters E., Kraal G., Hofker M.H. Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol 2005, 25(5):904-914.
28. Yates L.L., Goreck D.C. The nuclear factor-kappaB (NF-kappaB): from a versatile transcription factor to a ubiquitous therapeutic target. Acta Biochim Pol 2006, 53(4):651-662.
29. Hlawaty H., Jacob M.P., Louedec L., et al. Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis. Arterioscler Thromb Vasc Biol 2009, 29(4):518-524.
30. Seo K.W., Lee S.J., Kim C.E., et al. Participation of 5-lipoxygenase-derived LTB4 in 4-hydroxynonenal-enhanced MMP-2 production in vascular smooth muscle cells. Atherosclerosis 2010, 208(1):56-61.
31. Cave A. Selective targeting of NADPH oxidase for cardiovascular protection. Curr Opin Pharmacol 2009, 9(2):208-213.
32. Griendling K.K., Sorescu D., Ushio-Fukai M. NAD (P)H Oxidase: role in cardiovascular biology and disease. Circ Res 2000, 86:494-501.
33. Paravicini T.M., Touyz R.M. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 2008, 31(Suppl. 2):S170-S180.